BioDuro, a global life science research and development organization backed by Advent International (“Advent”), and Sundia, a leading contract research and manufacturing organization, today announced that they have partnered to create one of the largest CRDMOs (contract research, development, and manufacturing organizations) with major operations in China and the US. The combined company will operate as BioDuro-Sundia, providing fully integrated drug discovery, development, and manufacturing for both API (Active Pharmaceutical Ingredients) and drug products. Advent led a majority investment in Sundia, with Bridgewest Capital as co-investors. China eCapital Partners, LLC, the US affiliate of CEC Capital Group, served as Sundia’s financial advisor in this transaction.
On October 17, 2018, Ucommune and Fountown signed an agreement stipulating Ucommune’s acquisition of Fountown, which includes Ucommonue’s acquisition of Fountown’s 26 shared office space locations in Beijing and Shanghai. The transaction will strengthen Ucommune’s position as the IP behemoth of China’s shared office space industry. Beijing-based investment firm CEC Capital served as the exclusive financial adviser to Ucommune during the acquisition.